FIGURE 3.

(a) Observed and predicted number of SCRA exposes cases within each month between July 2015 to December 2019 based on segmented Poisson regression estimating trends before and after implementation of the PSA (see Table 1). (b) Observed and predicted number of non‐SCRA exposes cases within each month between July 2015 to December 2019 based on segmented Poisson regression estimating trends before and after implementation of the PSA (see Table 1). Note: Predicted number of cases refer to fitted values (and the 95% CI bands) of the final segmented Poison regression models reported in Table 1, whereas the observed cases are the true number of hospital presentations across the study period. SCRA, synthetic cannabinoid receptor agonist; PSA, Psychoactive Substances Act